vs
Side-by-side financial comparison of Evercore Inc. (EVR) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.4B vs $1.1B, roughly 1.3× PERRIGO Co plc). Evercore Inc. runs the higher net margin — 23.0% vs -127.8%, a 150.8% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs -2.5%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 1.3%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
EVR vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.1B |
| Net Profit | $322.7M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | — | -116.0% |
| Net Margin | 23.0% | -127.8% |
| Revenue YoY | 100.3% | -2.5% |
| Net Profit YoY | 106.1% | -3093.9% |
| EPS (diluted) | $7.20 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $838.0M | $1.1B | ||
| Q1 25 | $699.0M | $1.0B | ||
| Q4 24 | $979.5M | $1.1B | ||
| Q3 24 | $738.4M | $1.1B | ||
| Q2 24 | $693.4M | $1.1B |
| Q1 26 | $322.7M | — | ||
| Q4 25 | $204.0M | $-1.4B | ||
| Q3 25 | $144.6M | $7.5M | ||
| Q2 25 | $97.2M | $-8.4M | ||
| Q1 25 | $146.2M | $-6.4M | ||
| Q4 24 | $140.4M | $-44.4M | ||
| Q3 24 | $78.4M | $-21.0M | ||
| Q2 24 | $73.8M | $-108.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% |
| Q1 26 | — | — | ||
| Q4 25 | 24.2% | -116.0% | ||
| Q3 25 | 20.8% | 7.0% | ||
| Q2 25 | 18.0% | 4.3% | ||
| Q1 25 | 16.0% | 4.5% | ||
| Q4 24 | 21.8% | 10.0% | ||
| Q3 24 | 16.7% | 7.4% | ||
| Q2 24 | 15.9% | -2.5% |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 15.7% | -127.8% | ||
| Q3 25 | 13.8% | 0.7% | ||
| Q2 25 | 11.6% | -0.8% | ||
| Q1 25 | 20.9% | -0.6% | ||
| Q4 24 | 14.3% | -3.9% | ||
| Q3 24 | 10.6% | -1.9% | ||
| Q2 24 | 10.6% | -10.2% |
| Q1 26 | $7.20 | — | ||
| Q4 25 | $4.80 | $-10.23 | ||
| Q3 25 | $3.41 | $0.05 | ||
| Q2 25 | $2.36 | $-0.06 | ||
| Q1 25 | $3.48 | $-0.05 | ||
| Q4 24 | $3.32 | $-0.32 | ||
| Q3 24 | $1.86 | $-0.15 | ||
| Q2 24 | $1.81 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.9B |
| Total Assets | — | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.4B | $432.1M | ||
| Q2 25 | $1.7B | $454.2M | ||
| Q1 25 | $1.4B | $409.9M | ||
| Q4 24 | $2.4B | $558.8M | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.7B | $542.8M |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $1.8B | $4.4B | ||
| Q2 25 | $1.7B | $4.5B | ||
| Q1 25 | $1.5B | $4.4B | ||
| Q4 24 | $1.7B | $4.3B | ||
| Q3 24 | $1.6B | $4.6B | ||
| Q2 24 | $1.5B | $4.5B |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $8.5B | ||
| Q3 25 | $4.4B | $10.1B | ||
| Q2 25 | $3.7B | $10.1B | ||
| Q1 25 | $3.3B | $9.8B | ||
| Q4 24 | $4.2B | $9.6B | ||
| Q3 24 | $3.6B | $11.2B | ||
| Q2 24 | $3.3B | $10.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $807.5M | $175.4M | ||
| Q3 25 | $560.9M | $51.7M | ||
| Q2 25 | $437.7M | $75.9M | ||
| Q1 25 | $-549.7M | $-64.5M | ||
| Q4 24 | $686.4M | $312.6M | ||
| Q3 24 | $234.5M | $42.2M | ||
| Q2 24 | $348.5M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $798.6M | $148.6M | ||
| Q3 25 | $541.5M | $29.8M | ||
| Q2 25 | $411.7M | $56.7M | ||
| Q1 25 | $-569.3M | $-90.0M | ||
| Q4 24 | $673.1M | $274.9M | ||
| Q3 24 | $226.6M | $15.1M | ||
| Q2 24 | $340.7M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 61.6% | 13.4% | ||
| Q3 25 | 51.8% | 2.9% | ||
| Q2 25 | 49.1% | 5.4% | ||
| Q1 25 | -81.4% | -8.6% | ||
| Q4 24 | 68.7% | 24.2% | ||
| Q3 24 | 30.7% | 1.4% | ||
| Q2 24 | 49.1% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 2.4% | ||
| Q3 25 | 1.9% | 2.1% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 1.4% | 3.3% | ||
| Q3 24 | 1.1% | 2.5% | ||
| Q2 24 | 1.1% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.96× | — | ||
| Q3 25 | 3.88× | 6.89× | ||
| Q2 25 | 4.50× | — | ||
| Q1 25 | -3.76× | — | ||
| Q4 24 | 4.89× | — | ||
| Q3 24 | 2.99× | — | ||
| Q2 24 | 4.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
